Prof McDermott studied for his medical degree at the University in Leeds. He then continued his medical and specialist neurology training in Leeds followed by a clinical research training fellowship at the University of Newcastle upon Tyne. He moved to the University of Sheffield for his doctoral studies and to complete his Specialist Training in Neurology to become a Consultant Neurologist. Prof McDermott is now the Professor of Translational Neurology at SITraN and a Consultant Neurologist at the Sheffield Teaching Hospitals Foundation NHS Trust regularly undertaking specialist MND and neuromuscular clinics in Sheffield. The main drive of Prof McDermott’s research programme is developing the evidence base for delivering supportive and symptomatic care for patients living with motor neuron disease. He is chair of the NIHR UK MND Clinical Studies Group and is experienced in ALS clinical trials.
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.